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ABSTRACT
Friedreich ataxia (FRDA) is caused by a homozygous GAA repeat expansion 
mutation within intron 1 of the FXN gene, leading to reduced expression of 
frataxin protein. Evidence suggests that the mutation may induce epigenetic 
changes and heterochromatin formation, thereby impeding gene transcription. In 
particular, studies using FRDA patient blood and lymphoblastoid cell lines have 
detected increased DNA methylation of specific CpG sites upstream of the GAA 
repeat and histone modifications in regions flanking the GAA repeat. In this 
report we show that such epigenetic changes are also present in FRDA patient 
brain and heart tissues, the primary affected systems of the disorder. Bisulfite 
sequence analysis of the FXN flanking GAA regions reveals a shift in the FRDA 
DNA methylation profile, with upstream CpG sites becoming consistently 
hypermethylated and downstream CpG sites becoming consistently 
hypomethylated. We also identify differential DNA methylation at three specific 
CpG sites within the FXN promoter and one CpG site within exon 1. Furthermore, 
we show by chromatin immunoprecipitation (ChIP) analysis that there is overall 
decreased histone H3 and H4 acetylation together with increased H3K9 
methylation of FRDA brain tissue. Further studies of brain and heart tissues from 
our GAA repeat expansion-containing FRDA YAC transgenic mice reveal 
comparable epigenetic changes to those detected in FRDA patient tissue. We 
have thus developed a mouse model that will be a valuable resource for future 
therapeutic studies targeting epigenetic modifications of the FXN gene to 
increase frataxin expression.
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INTRODUCTION
FRDA is an autosomal recessive neurodegenerative disorder that is 
predominantly caused by a homozygous GAA repeat expansion mutation within 
intron 1 of the FXN gene (1). Normal individuals have 5 to 30 GAA repeat 
sequences, whereas affected individuals have from approximately 70 to more 
than 1,000 GAA triplets (2). The GAA repeat shows somatic instability, with 
progressive expansion throughout life, particularly in the cerebellum and dorsal 
root ganglia (DRG) (3-5). The effect of the GAA expansion mutation is to reduce 
the expression of frataxin (6), a mitochondrial protein that acts as an iron 
chaperone in iron-sulphur cluster and heme biosynthesis (7-9). Frataxin 
insufficiency leads to oxidative stress, mitochondrial iron accumulation and 
resultant cell death, with the primary site of pathology being in the large sensory 
neurons of the DRG and the dentate nucleus of the cerebellum (10). The 
outcome is progressive spinocerebellar neurodegeneration, causing symptoms of 
ataxia, dysarthria, muscle weakness, and sensory loss, together with 
cardiomyopathy, and diabetes. At present there is no effective treatment for 
FRDA, and affected individuals generally die in early adulthood from the 
associated heart disease.
Preclinical and clinical trials using antioxidants and iron chelators have 
demonstrated some limited success in alleviating FRDA heart pathology (11-16). 
However, a more effective overall therapeutic strategy may be to target the 
immediate effects of the GAA repeat expansion mutation to restore normal levels 
of frataxin expression. The exact mechanism by which the GAA repeat 
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expansion leads to decreased frataxin expression is unknown, but several 
models have been put forward. Firstly, it has been suggested that the GAA 
repeat expansion may adopt abnormal DNA or DNA/RNA hybrid structures that 
interfere with FXN gene transcription (17-20). Secondly, there is evidence that 
GAA repeat expansions produce a heterochromatin-mediated gene silencing 
effect (21). Epigenetic mechanisms, such as DNA methylation and the 
associated deacetylation and methylation of histones are known to affect gene 
expression by chromatin remodelling (22), and these epigenetic changes are 
likely to underpin any GAA repeat-induced heterochromatin-mediated gene 
silencing effects. In support of this hypothesis, research has recently shown 
increased DNA methylation of three specific CpG sites immediately upstream of 
the expanded GAA repeat sequence in FRDA patient lymphoblastoid cell lines 
and primary lymphocytes, and one of the three CpG sites was identified as an 
important enhancer of frataxin expression (23). Other studies have identified 
specific histone modifications that are associated with gene silencing within the 
GAA repeat expansion-flanking regions of the FXN intron 1 sequence in FRDA 
lymphoblastoid cell lines and primary lymphocytes (23, 24). These changes 
include deacetylation of histone H3 and H4 lysine residues and increased di- and 
trimethylation of H3K9. Based on the hypothesis that the acetylation state of the 
core histones is responsible for gene silencing, novel histone deacetylase 
(HDAC) inhibitor compounds have been developed and have been shown to 
increase FXN transcription in FRDA lymphoblastoid cells and primary 
lymphocytes (24). 
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These previous epigenetic studies have provided valuable insights into the 
possible mechanism of GAA-induced transcription inhibition, but they do not 
address the issue of whether such epigenetic changes are actually present in the 
most clinically relevant FRDA tissues. Therefore, we decided to investigate 
epigenetic profiles of the FXN gene in FRDA patient autopsy brain and heart 
tissue. By bisulfite sequencing and ChIP analysis we now report changes in DNA 
methylation and histone modifications that are consistent with inhibition of FXN
transcription. With a view to future epigenetic-based FRDA therapies, we also 
investigated the FXN epigenetic profiles within brain and heart tissue from our 
Y47, YG8 and YG22 FRDA YAC transgenic mouse models (25-27). We find that 
the GAA repeat expansion-containing FRDA mouse models (YG8 and YG22) 
exhibit comparable epigenetic changes to those detected in FRDA patient tissue. 
Therefore, these are excellent FRDA mouse models in which to investigate the 
therapeutic effects of epigenetically-acting compounds, such as novel HDAC 
inhibitors or DNA methylation inhibitors.
RESULTS
FXN gene DNA methylation profiles are distinctly altered in human FRDA 
brain and heart tissues
A previous investigation of the FXN gene in FRDA patient lymphoblastoid cell 
lines and blood samples has detected hypermethylation at three specific CpG 
sites immediately upstream of the expanded GAA repeat sequence. One of the 
three CpG sites was further identified as an important enhancer element for 
Page 5 of 39 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
6
frataxin expression (23). This same study also reported a lack of any DNA 
methylation in the promoter region of either FRDA or unaffected cells.
However, cultured cells are known to often develop non-physiological DNA 
methylation profiles. Furthermore, FRDA is a systemic disorder that is known to 
have differentially affected tissues and cell types. Therefore, we chose to 
investigate the DNA methylation status in two of the primary affected tissues in 
FRDA, namely brain and heart. We obtained brain and heart autopsy tissues 
from an FRDA patient (GAA repeat sizes of 750 and 650) and an unaffected 
individual, and we firstly determined the FXN transcription levels of the samples 
by quantitative RT-PCR. The FRDA brain and heart samples showed 12% and 
67% FXN expression, respectively, compared with the unaffected samples (Fig. 
1). We then analysed the DNA methylation status of the samples by performing 
bisulfite sequence analysis of three regions of the FXN gene: (i) a 475bp 
sequence that encompasses part of the FXN promoter, exon 1 and start of intron 
1, containing 59 CpG sites; (ii) a 286bp sequence upstream of the GAA repeat, 
containing 8 CpG sites, and (iii) a 275bp sequence downstream of the GAA 
repeat, containing 12 CpG sites (Fig. 2). A comparison of the bisulfite sequences 
from the FRDA patient and control brain and heart tissues reveals a certain 
degree of DNA methylation in all 8 of the upstream GAA CpG sites (Fig. 3C and 
D) and all 12 of the downstream GAA CpG sites (Fig. 3E and F). However, the 
data show a consistent shift in the DNA methylation pattern around the GAA 
repeat in both tissue types. The FRDA upstream GAA CpG sites are 
comparatively hypermethylated, whereas the FRDA downstream GAA CpG sites 
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are comparatively hypomethylated (Fig. 3C-F). The greatest increase in DNA 
methylation within the upstream GAA region is seen at CpG site 4. Significantly 
increased DNA methylation is also seen at CpG sites 5 and 6, the latter of which 
corresponds to the previously described E-box enhancer element (23). We 
observed 100% methylation at CpG site 6 in FRDA brain tissue (FXN mRNA 
level of 12%, Fig.1) compared with 80% methylation in heart tissue (FXN mRNA 
level of 67%, Fig.1). Thus, the upstream GAA DNA methylation changes in both 
FRDA brain and heart are consistent with their proposed roles in inhibition of 
FXN transcription. However, the finding of decreased DNA methylation in the 
downstream GAA region (Fig. 3E and F) is somewhat unexpected, since all of 
the 12 CpG sites fall within an Alu repeat sequence and such sequences are 
usually repressed by heavy DNA methylation.  
Another particularly interesting finding was the identification of differential DNA 
methylation at three specific CpG sites within the FXN promoter (sites 5, 7 and 8) 
and one CpG site within exon 1 (site 23) (Fig. 3A and B). All of the other 55 CpG 
sites in the total of 59 CpG sites analysed show complete lack of DNA 
methylation, as to be expected for a CpG island that is situated at the start of a 
gene. CpG sites 5, 7 and 8 show incomplete methylation in the unaffected heart, 
but complete methylation in the FRDA heart (Fig. 3B). Therefore, these CpG 
sites may be involved in reducing initiation of FXN gene transcription in FRDA
heart. However, the DNA methylation pattern is different in brain tissue. Here we 
identified approximately 20% DNA methylation at all of the four CpG sites in the 
unaffected tissue, but very little change, and even a decrease, in DNA 
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methylation in FRDA tissue (Fig. 3A). Furthermore, the fact that we have 
identified some degree of DNA methylation at all in this region contrasts with the 
previous report that DNA methylation is absent in the FXN promoter region of 
both FRDA and unaffected lymphoblastoid cells (23). Therefore, we have shown 
that the influence of DNA methylation on FXN gene expression is likely to be 
complex, with some similarities (CpG site usage) but also some distinct 
differences (degree of CpG methylation) identified between different somatic 
tissues.  
FXN gene histone modifications are altered in human FRDA brain tissue
Previous studies of the promoter, upstream GAA and downstream GAA regions 
of the FXN gene have identified specific histone modifications that are associated 
with gene silencing within the GAA repeat expansion-flanking regions of the FXN
intron 1 sequence in FRDA lymphoblastoid cell lines and primary lymphocytes 
(23, 24). We have now investigated acetylated histone H3 and H4 and 
methylated histone H3K9 modifications by ChIP analysis of the FXN promoter, 
upstream GAA and downstream GAA regions (Fig. 2) in autopsy brain tissues 
from an FRDA patient and an unaffected individual. Our results show overall 
decreased histone H3 and H4 acetylation of FRDA brain tissue, particularly in the 
downstream GAA region (Fig.4). All of the 6 acetylated histone residues that we 
have examined show a GAA-induced gradient of comparative acetylation that is 
highest in the FXN promoter and lowest in the downstream GAA region. The 
single most altered histone residue is H3K9, which exhibits progressive 
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decreases in acetylation to comparative levels of 63%, 35% and 9% in the FXN
promoter, upstream GAA and downstream GAA regions, respectively. There is 
also a consistently increased H3K9 di- and tri-methylation of FRDA brain tissue 
in all three of the FXN gene regions (Fig. 4). These changes concur with the 
previous findings of increased H3K9 di- and tri-methylation in the upstream GAA 
region of other cell types (23, 24). However, we have now extended these 
studies to show that in FRDA brain the H3K9 di- and tri-methylation spreads to 
both FXN promoter and downstream GAA regions.
DNA methylation profiles of FXN transgenic mouse brain and heart tissues 
resemble the profiles of human tissue
Having determined the epigenetic profiles around the human FXN gene, we then 
investigated the epigenetic profiles of the FXN transgene in brain and heart 
tissue isolated from YG8 and YG22 GAA repeat expansion-containing FXN YAC 
transgenic mice (26) compared with Y47 normal-sized GAA repeat-containing 
FXN YAC transgenic mice (27). Initial determination of FXN transgene 
expression showed YG8 (90+190 GAA repeats) and YG22 (190 GAA repeats) to 
have decreased mRNA levels of approximately 26% and 35% in brain and 57% 
and 56% in heart compared with Y47 (Fig. 5). Thus, inhibition of FXN expression 
in transgenic mouse brain was not as severe as the 12% observed in the 
750/650 GAA repeat-containing human FRDA brain (Fig. 1), whereas levels of 
FXN expression in heart were more comparable. DNA methylation analysis was 
then performed on the single GAA repeat expansion-containing YG22 GAA 
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repeat transgenic mouse compared to the Y47 non-GAA repeat control. As the 
mouse transgenes consist of entire human FXN gene sequence, we were able to 
investigate the DNA methylation profiles of exactly the same three regions of the 
FXN gene that we had previously analysed in human tissue (Fig. 2). Our data 
show that the DNA methylation profiles of upstream GAA regions of both YG22 
transgenic mouse brain and heart tissues closely resemble those found in human 
tissues (Fig. 6C and D). Namely, there is a consistent hypermethylation of the 
upstream GAA region induced by the GAA repeat expansion, with the most 
prominent hypermethylation at CpG sites 4, 5 and 6. However, the degree of 
DNA methylation at CpG sites 4 and 6 in YG22 transgenic mouse brain tissue is 
less than that observed in FRDA human brain tissue, which is consistent with the 
comparative FXN expression levels of 35% and 12%, respectively (Figs. 1 and 
5). The downstream GAA region differs from the human situation in that there is 
hypermethylation at all CpG sites, which is retained upon introduction of the GAA 
repeat expansion (Fig. 6E and F). Thus, there is no GAA-induced decrease in 
DNA methylation as detected in the human tissues. The promoter/exon 1 regions 
of the FXN transgenes in both mouse brain and heart tissues show a similarity to 
the human tissues in that DNA methylation is found at only four specific CpG 
sites: 5, 7, 8 and 23 (Fig. 6A and B). However, the changes in the DNA profiles of 
these four CpG sites upon introduction of the GAA repeat expansion differ 
markedly from those found in the human tissues. This time, the brain tissue 
shows an overall increase in DNA methylation, whereas the heart tissue shows 
an overall decrease in DNA methylation. Assessment of the entire mouse DNA 
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methylation data indicates a similar overall DNA methylation profile around the 
start of the FXN gene that is consistent with inhibition of FXN transcription. 
However, there are also some specific differences, which may result from 
epigenetic-control or transcriptional-control variations between the human and 
the mouse that will require further investigation.
Histone modifications of FXN transgenic mouse brain tissue are 
comparable to hist ne modifications of human tissue
Acetylated histone H3 and H4 and di- and tri-methylated histone H3K9 
modifications were detected by ChIP analysis of the three regions of the FXN
transgene (Fig. 2) in brain tissue isolated from both YG8 and YG22 GAA repeat 
expansion-containing FXN YAC transgenic mice (26) and Y47 normal-sized GAA 
repeat-containing FXN YAC transgenic mice (27). Our results show overall GAA 
repeat-induced decreases in histone H3 and H4 acetylation and increases in 
H3K9 methylation for both YG8 and YG22 transgenic mice (Fig. 7), as we 
previously identified in human FRDA tissue (Fig. 4). However, the level of 
deacetylation in the transgenic mouse tissue was not as great as that seen in the 
human tissue, possibly as a consequence of the smaller transgenic GAA repeat 
expansion sizes (190+90 for YG8 and 190 for YG22, compared with 750/650 for 
FRDA patient). Also, H4K16 acetylation is actually increased in all three FXN
transgene regions of both YG8 and YG22 compared with Y47, which is different 
to the finding in human tissues. The greatest consistent histone residue changes 
that we found between the non-GAA (Y47) and both of the GAA (YG8 and YG22) 
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transgenic brain tissue samples were decreases in acetylated H3K9 and 
increases in di- and tri-methylated H3K9. The H4K12 residue also showed a 
significant degree of deacetylation, but only in the YG8 transgenic tissue. All of 
these major histone residue changes in mouse brain tissue reflect the GAA 
repeat-induced histone residue changes that we detected in human tissue. 
Furthermore, as with the human samples, we similarly identified a GAA repeat-
induced gradient of decreased H3K9 acetylation in both YG8 and YG22 
transgenic mouse tissues, with the highest comparative levels of acetylation in 
the FXN promoter and the lowest comparative levels in the downstream GAA 
region. The increases in H3K9 di- and tri-methylation were consistent throughout 
all of the three FXN gene regions in both YG8 and YG22 transgenic mice, once 
again agreeing with our findings in human FRDA tissue.
DISCUSSION
For the consideration of future FRDA therapy, it is first essential to understand 
the mechanism of GAA-induced inhibition of FXN gene transcription. Previous
studies of FRDA have implicated epigenetic changes, including the detection of 
increased DNA methylation of specific CpG sites upstream of the GAA repeat 
and histone modifications in regions flanking the GAA repeat that are both 
consistent with transcription inhibition (23, 24). However, no DNA or histone 
methylation changes have previously been identified in the FXN promoter or 
downstream GAA regions, and clinically relevant FRDA brain and heart tissues 
have not previously been investigated. Different trinucleotide repeat expansion 
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mutations have been shown to induce cis-acting epigenetic changes in several 
other human disorders (28, 29). Thus, DNA methylation of the CGG repeat 
upstream of the FMR1 gene has been identified as a main epigenetic switch in 
Fragile X syndrome, with histone acetylation playing an ancillary role (30). 
Decreased Sp1 interaction associated with DNA hypermethylation upstream of 
the CTG repeat in the DMPK gene has also been reported for congenital 
myotonic dystrophy type 1 (29). Furthermore, both CTG and GAA repeat 
expansions have been shown to induce similar heterochromatin formation by 
position effect variegation studies of transgenic mice (21). However, it is still 
uncertain if different trinucleotide repeat sequences produce similar overall 
epigenetic effects or not.
Our investigations of the FXN gene in both FRDA human and transgenic 
mouse brain and heart tissues have now confirmed the presence of previously 
described DNA methylation changes (23) in the upstream GAA region of these 
clinically important tissues. Furthermore, our data have revealed an overall shift 
in the DNA methylation profile, moving from hypomethylation in the downstream 
GAA region towards hypermethylation in the upstream GAA region. This shift in 
DNA methylation profile could be explained by the known position of the GAA 
repeat within an Alu sequence, since Alu sequences have been shown to act as 
methylation centres leading to bi-directional spread of DNA methylation (31). 
Thus, the hypermethylation detected in the FRDA upstream GAA region may be 
due to the GAA repeat mutation enhancing the effect of a putative methylation 
centre at the 5’ end of the Alu sequence. At the same time, the addition of the 
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GAA repeat sequence would put extra distance between the methylation centre 
at the 5’ end of the Alu sequence and the downstream GAA region. This may 
impede the spread of methylation to the downstream region when the distance is 
large enough (2.25kb for 750 human GAA repeats), but not when the distance is 
smaller (600bp for 190 transgenic mouse GAA repeats). 
We have additionally identified differential DNA methylation at four specific 
CpG sites within the FXN promoter and exon 1 regions that have not previously 
been reported. The three CpG sites within the promoter region (sites 5, 7 and 8) 
are immediately upstream of the ATG translation start site, at nucleotide 
positions –27, -18 and –11, respectively. CpG sites 5 and 7 are also contained 
within Sp1 transcription factor binding sites (32). Interestingly, the region 
between –64 and the start of translation has previously been suggested to 
contain sequences important for positive regulation of frataxin production, 
although no candidate sequences were identified (33). Therefore, the 3 
differentially methylated CpG sites that we have now uncovered in the FXN
promoter, and in particular the two Sp1 recognition sites, are likely to represent 
these important regulatory sequences. 
By comparison with other instances of trinucleotide repeat-induced DNA 
methylation changes that inhibit transcription (28, 29), one would have predicted 
general hypermethylation to be associated with the FRDA GAA repeat expansion 
mutation. However, we actually identified three occurrences in human tissues 
(promoter and downstream GAA regions in brain, and downstream GAA region in 
heart) and one occurrence in mouse tissues (promoter region in heart) where 
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there was in fact GAA repeat expansion-induced decrease in DNA methylation. 
This suggests the possible occurrence of demethylation and resultant active FXN
gene expression, at least for some cells within the tissue. DNA demethylation 
has previously been shown to occur both passively due to DNA replication upon 
cell division (34) and actively in a process that may involve RNA (35), although 
the DNA demethylating activity has yet to be identified. DNA demethylation has 
also previously been associated with processes of DNA damage and repair. The 
formation of 8-OH-dG by oxidative DNA damage has been shown to affect the 
activity of human DNA methyltransferase and inhibit CpG methylation (36), and 
DNA demethylation has also been shown to occur as a result of homologous 
recombination repair of DNA damaged by double-strand breaks (37). However, 
DNA demethylation has not previously been considered for FRDA. A close 
inspection of our data reveals potential DNA demethylation in the FXN promoter 
region only when CpG site 6 of the upstream GAA region is 100% methylated. 
Therefore, we now propose that the shutdown of transcription due to major 
epigenetic changes at the upstream GAA region may result in attempts to 
upregulate FXN transcription by Sp1 binding and subsequent DNA demethylation 
in the promoter region. In support of this proposal, Sp1 binding is known to occur 
independent of CpG methylation status (32), but at the same time has been 
shown to inhibit CpG methylation (38). Furthermore, DNA demethylation has 
previously been shown to occur when there are few methylated CpG sites within 
a CpG island, but not when all of the CpG sites are methylated (39), which is 
exactly the situation that we find for the FXN promoter region. However, the GAA 
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repeat expansion-induced decreases in DNA methylation at the FXN promoter 
are not consistent throughout all human and mouse brain and heart tissues, 
suggesting the involvement of other factors. Such factors may include differential 
susceptibility of the brain and heart tissues to DNA damage and/or GAA repeat 
instability. Indeed, FRDA is a disorder that is known to involve both oxidative 
DNA damage (40) and somatic instability of GAA repeats (3-5). Therefore, cells 
that are initially methylated at the FXN promoter region may lose this methylation 
as part of the GAA repeat instability process, wherein demethylation subsequent 
to DNA damage repair (37) may be selected for due to beneficial effect of FXN
expression and hence cell viability. The GAA repeat expansion-induced 
decreases in DNA methylation that we have observed in the downstream GAA 
region of human tissues, but not transgenic mouse tissues, are more likely due to 
differently sized GAA repeats within the Alu sequence, as we have previously 
discussed. However, potential DNA demethylation in this downstream GAA 
region could also indirectly lead to an increase in FXN transcription due to the 
removal of inhibitory effects on RNA polymerase II elongation.
Our investigations of histone modifications within FXN gene in both FRDA 
human and transgenic mouse brain tissues have now confirmed the changes 
previously reported for H3 and H4 deacetylation in the FXN promoter, upstream 
GAA and downstream GAA regions and H3K9 methylation in the upstream GAA 
region (23, 24). Furthermore, we have extended the H3K9 methylation analysis 
to include the FXN promoter and downstream GAA regions that to our knowledge 
have not previously been reported for any FRDA tissue. Our findings from both 
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human and transgenic mouse tissues indicate significant H3K9 deacetylation, 
which becomes more severe upon progression from the FXN promoter, through 
the upstream GAA region to the downstream GAA region. This correlates well 
with the results for both di- and tri-methylation of H3K9, which show a generally 
similar gradient of progressive increase from the FXN promoter, through the 
upstream GAA region, to the downstream GAA region. The only exception is the 
very high level of di-methylated H3K9 in FRDA brain tissue, which is higher than 
that in the downstream GAA region. All of the H3K9 changes correlate well with 
the DNA methylation changes in both human and transgenic mouse brain 
tissues. Thus, the patterns of progressively increasing H3K9 deacetylation and 
increasing H3K9 di- and tri-methylation in transgenic mouse brain correspond 
exactly to the pattern of increasing DNA methylation. Similarly, the patterns of 
progressively increasing H3K9 deacetylation and increasing H3K9 tri-methylation 
in human FRDA brain with a peak of H3K9 di-methylation in the upstream GAA 
region equate very well to the corresponding DNA methylation profiles. 
Therefore, our combined data thus far indicate major roles for DNA methylation, 
histone H3K9 deacetylation and histone H3K9 methylation in the inhibition of 
FXN transcription in brain and heart tissues, with a less prominent role for 
deacetylation of other histone residues. The more severe epigenetic changes 
within the FXN intron 1 region compared with the promoter region support a 
hypothesis of transcription inhibition due to interference with elongation rather 
than initiation. Further work will be required to determine the exact relationships 
between DNA methylation, histone acetylation and methylation, heterochromatin 
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formation and transcription inhibition.  However, our results are consistent with 
the generally described pathway for gene inactivation wherein initial histone 
H3K9 deacetylation leads to H3K9 methylation, recruitment of HP1, histone 
deacetylases, DNA methyltransferases and eventual long-term shut down of 
transcription by DNA methylation (41). However, this situation is not likely to be 
universal for all trinucleotide repeat disorders, as highlighted by research on the 
FMR1 gene which has shown both histone deacetylation and H3K9 methylation 
in the absence of DNA methylation without interfering in active gene transcription 
(42).
For now, the exact mechanism by which the GAA repeat mutation inhibits 
frataxin expression remains elusive. However, accumulating evidence, including 
the findings of this report, now highlights the importance of epigenetic changes 
that lead to heterochromatin formation. The epigenetic changes that we and 
others have now identified in FRDA do not in any way negate the importance of 
any abnormal DNA or DNA/RNA hybrid structures in the inhibition of frataxin 
expression, but rather suggest the involvement of several combined 
mechanisms. Indeed the existence of abnormal DNA structures may help to 
explain why the GAA repeat mutation induces epigenetic changes in the first 
place. Thus, there are reports that non-B DNA structures such as hairpins may 
induce DNA methylation (43, 44), and GAA repeats have been shown to form 
hairpins (45). Alternatively, small double-stranded RNA (dsRNA) has also been 
shown to induce transcriptional gene silencing through a mechanism that 
involves DNA methylation (46, 47). However, dsRNA has failed to induce DNA 
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methylation in a study of mouse oocytes (48) and dsRNA targeted to the HD
gene does not induce DNA methylation at the target huntingtin genomic locus in 
human cells (49). Thus, further studies are still required to identify any possible 
involvement of non-B DNA structures (such as GAA hairpins or triplex 
structures), DNA/RNA hybrids or dsRNA in the establishment of epigenetic 
changes and heterochromatin formation in FRDA.
In light of the epigenetic changes that we and others have identified in 
FRDA tissues and cells, several novel epigenetic-based therapeutic approaches 
can now be considered for FRDA. Firstly, histone deacetylase (HDAC) inhibitors 
can be used, and indeed these have already shown considerable promise by 
decreasing acetylation of histones and thereby increasing FXN transcription in 
FRDA cells (24). Secondly, pharmacological approaches could be taken to 
decrease H3K9 methylation, as have recently been described for the combined 
use of mithramycin and cystamine in Huntington disease mice (50). Thirdly, 
therapies to decrease DNA methylation should now be considered for FRDA, as 
have previously been tried for other trinucleotide repeat disorders. In particular, 
5-azadeoxycytidine (5-azadC) has been shown to remove DNA methylation of 
the CCG repeat expansion, increase H3 and H4 acetylation, decrease H3K9 
methylation, increase H3K4 methylation and reactivate the FMR1 gene (30, 51).
Combined HDAC inhibitor and 5-azadC treatment has also been shown to 
synergistically increase FMR1 gene activity (52). Finally, short dsRNA molecules 
complementary to promoter sequences have recently been shown to induce 
gene activation (53, 54), and such approaches may also prove effective in 
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increasing FXN transcription. Our identification of a transgenic FRDA mouse 
model that shows comparable epigenetic changes to those seen in FRDA 
patients will now provide a valuable resource in the study of all such epigenetic-
based FRDA therapies.
MATERIALS AND METHODS
Tissues. Human brain and heart tissue samples were obtained from autopsies of 
an FRDA patient (750/650 GAA repeats) and a non-FRDA individual, in 
accordance with UK Human Tissue Authority ethical guidelines. Mouse brain and 
heart tissues were dissected from our previously reported FXN YAC transgenic 
mouse models: Y47 (2 copies of 9 GAA repeats); YG8 (2 copies of 90 and 190 
GAA repeats), and YG22 (1 copy of 190 GAA repeats) (25, 27).
mRNA expression analysis. Total RNA was isolated from frozen tissues by 
homogenization with Trizol (Invitrogen) and cDNA was then prepared by using 
AMV Reverse transcriptase (Invitrogen) with oligo-dT primers. Levels of human 
or mouse transgenic FXN mRNA expression were assessed by quantitative RT-
PCR using an ABI7400 sequencer and SYBR® Green (Applied Biosystems) with 
the following primers: FxnRTF 5’-CAGAGGAAACGCTGGACTCT-3’
and FxnRTR 5’-AGCCAGATTTGCTTGTTTGGC-3’
(24). Human GAPDH or mouse Gapdh RT-PCR primers were used as control 
standards: human: GapdhhF 5’-GAAGGTGAAGGTCGGAGT-3’ and
GapdhhR 5’-GAAGATGGTGATGGGATTTC-3’
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mouse GapdhmF 5’-ACCCAGAAGACTGTGGATGG-3’ and GapdhmR 5’-
GGATGCAGGGATGATGTTCT-3’
Bisulfite sequencing. Genomic DNA was isolated from frozen tissue by 
standard phenol/chloroform extraction and ethanol precipitation. 2ug of genomic 
DNA was digested with EcoRI prior to bisulfite treatment using the CpGenome kit 
(Calbiochem). Nested PCR was carried out on bisulfite-treated DNA to amplify 
three regions of the FXN gene using the following primers: Pro 1st primer pair: 
SL1F1 5’-TAGTTTTTAAGTTTTTTTTGTTTAG-3’ and SL1R1 5’-
CAAAACAAAATATCCCCTTTTC-3’; Pro 2nd primer pair: SL1F2 5’-
GTTTTTTTATAGAAGAGTGTTTG-3’ and SL1R2 5’-
CAAAAACCAATATAAATACAACC-3’; Up 1st primer pair: F1G 5’-
GAGGGATTTGTTTGGGTAAAG-3’ and R1G 5’-
ATACTAAATTTCACCATATTAACC-3’; Up 2nd primer pair: F2G 5’-
GATTTGTTTGGGTAAAGGTTAG-3’ and R2G 5’-
CTCCCAAAATACTAAAATTATAAAC-3’; Down 1st primer pair: NH1F 5’-
AAGAAGAAGAAGAAAATAAAGAAAAG-3’ and SLGR2 5’-
TCCTAAAAAAAATCTAAAAACCATC-3’; Down 2nd primer pair: NH2F 5’-
AGAAGAAGAAAATAAAGAAAAAGTTAG-3’ and SLGR1 5’-
AAAACCATCATAACCACACTTAC-3’. PCR products were then resolved on 
agarose gels, purified with Geneclean (BIO101) and cloned into pCR4.0 
(Invitrogen) prior to DNA sequencing. A minimum of 8 clones were sequenced for 
each tissue sample.
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ChIP analysis. Histone modifications at the three FXN gene regions were 
detected by ChIP analysis of FRDA human and mouse tissues. This procedure 
involved initial cross-linking of DNA and protein by formaldehyde treatment of 
homogenised frozen tissue samples. DNA was then sheared by sonication, 
followed by immunoprecipitation with commercially available anti-histone and 
anti-acetylated histone H3 and H4 antibodies: H3K9ac, H3K14ac, H4K5ac, 
H4K8ac, H4K12ac, H4K16ac and H3K9me2 (Upstate), and H3K9me3 
(Diagenode). For each experiment, normal rabbit serum (SIGMA) was used as a 
minus antibody immunoprecipitation control. After reversal of cross-linking, 
quantitative RT-PCR amplification of the resultant co-immunoprecipitated DNA 
was carried out with SYBR® Green in an ABI7400 sequencer (Applied 
Biosystems) using three sets of FXN primers (Pro, Up and Down) and human 
GAPDH control for the human samples as previously described (24). For the 
analysis of transgenic mouse samples, the same three sets of FXN primers were 
used together with the following mouse Gapdh control primers: GapdhMF, 5’-
TGACAAGAGGGCGAGCG-3’ and GapdhMR, 5’-GGAAGCCGAAGTCAGGAAC-
3’. Each tissue sample was subjected to two independent ChIP procedures, 
followed by triplicate quantitative PCR analysis. 
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LEGENDS TO FIGURES
Figure 1. Quantitative RT-PCR analysis of FXN mRNA isolated from brain and 
heart autopsy samples of an FRDA patient (750 and 650 GAA repeats) and an 
unaffected individual. Data are normalised to the FXN mRNA level found in the 
unaffected individual. Two individual cDNA samples were analysed for each 
tissue and each reaction was carried out in triplicate. The means and SEMs of 
these values are shown.
Figure 2. Schematic representation of 2.2kb at the 5’ end of the FXN gene, 
indicating the promoter / exon 1 (Pro), upstream GAA (Up) and downstream GAA 
(Down) regions that were analysed by ChIP (black boxes) and bisulfite 
sequencing (hatched boxes). Numbers above indicate the position of CpG sites 
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within the promoter and upstream GAA regions. The positions of the ATG 
translation start codon, exon 1 open reading frame and GAA repeat sequence 
within the Alu repeat sequence are shown. Numbers below indicate the 
chromosome 9 base pair numbering according to the 2006 build of the UCSC 
human DNA sequence database. 
Figure 3. DNA methylation analysis of the FXN promoter (A, B), upstream GAA 
(C, D) and downstream GAA (E, F) regions of human brain and heart tissues. In 
each case the percentage of methylated CpG sites is shown as determined from 
the analysis of 8 to 12 independent cloned DNA sequences. Only eleven CpG 
sites are represented for the promoter region (A, B), as sites 11-22 and 24-59 did 
not show any methylation in either FRDA or unaffected samples in brain or heart. 
Figure 4. Analysis of histone modifications in human brain tissue. ChIP 
quantitative PCR results for the FXN promoter/exon1 (Pro), upstream GAA (Up) 
and downstream GAA (Down) amplified regions are r presented as the relative 
amount of immunoprecipitated DNA compared with input DNA, having taken 
negligible –Ab control values into account. FXN values were normalised with 
human GAPDH and all values have been adjusted so that all of the Upstream 
GAA values from the unaffected individual are 100%. In each case two individual 
ChIP samples were analysed in triplicate. The means and SEMs of these values 
are shown.
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Figure 5. Quantitative RT-PCR analysis of transgenic FXN mRNA isolated from 
Y47, YG8 and YG22 mouse brain and heart tissues. Data are normalised to the 
FXN mRNA level found in the non-GAA transgenic mouse. Two individual cDNA 
samples were analysed for each tissue and each reaction was carried out in 
triplicate. The means and SEMs of these values are shown.
Figure 6. DNA methylation analysis of the FXN promoter (A, B), upstream GAA 
(C, D) and downstream GAA (E, F) regions of YG22 (GAA) and Y47 (non-GAA) 
transgenic mouse brain and heart tissues. In each case the percentage of 
methylated CpG sites is shown as determined from the analysis of 8 to 25 
independent cloned DNA sequences. Only eleven CpG sites are represented for 
the promoter region, as sites 11-22 and 24-59 did not show any methylation in 
either FRDA or unaffected samples in brain or heart.
Figure 7. Analysis of histone modifications in transgenic mouse brain tissue. 
ChIP quantitative PCR results for the transgenic FXN promoter/exon1 (Pro), 
upstream GAA (Up) and downstream GAA (Down) amplified regions are 
represented as the relative amount of immunoprecipitated DNA compared with 
input DNA, having taken negligible –Ab control values into account.. FXN values 
were normalised with mouse GAPDH and all values have been adjusted so that 
all of the upstream GAA values from the non-GAA transgenic mouse (Y47) are 
100%. In each case two individual ChIP samples were analysed in triplicate. The 
means and SEMs of these values are shown.
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Fig. 3
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Fig. 6
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Fig.7
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ABBREVIATIONS
5-azadC: 5-azadeoxycytidine; 8-OH-dG: 8-hydroxyl-2’-deoxyguanosine; Ab: 
antibody;  ChIP: chromatin immunoprecipitation; DRG: dorsal root ganglia; 
FRDA: Friedreich ataxia; GAPDH: glyceraldehyde-3-phosphate 
dehydrogenase; H3K9: histone 3 lysine 9 residue; HDAC: histone deacetylase; 
HP1: heterochromatin protein 1; RT-PCR: reverse transcriptase polymerase 
chain reaction; SEM: standard error of the mean; Sp1: specificity protein 1.
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